This “CD33 antigen inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in CD33 antigen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CD33 antigen inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CD33 antigen inhibitors pipeline landscape is provided which includes the disease overview and CD33 antigen inhibitors treatment guidelines. The assessment part of the report embraces, in depth CD33 antigen inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CD33 antigen inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
CD33 antigen inhibitors Understanding
CD33 antigen inhibitors: Overview
Siglec-3 has been known as CD33 for over 20 years and has been studied as a myeloid lymphoma marker in the clinical research, long before any other Siglec was known. Siglec-3 has an apparent molecular mass of 67 kDa on sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) while its predicted mass is 40 kDa. This is due to the glycosylation of Siglec-3 with its five potential glycosylation sites. This protein has two Ig-like domains, one V-set domain and one C2-set domain, and is the smallest member of the Siglec family. CD33 can be stimulated by any molecule with sialic acid residues such as glycoproteins or glycolipids. Upon binding, the immunoreceptor tyrosine-based inhibition motif (ITIM) of CD33, present on the cytosolic portion of the protein, is phosphorylated and acts as a docking site for Src homology 2 (SH2) domain-containing proteins like SHP phosphatases. This results in a cascade that inhibits phagocytosis in the cell.CD33 antigen inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CD33 antigen inhibitors pipeline landscape is provided which includes the disease overview and CD33 antigen inhibitors treatment guidelines. The assessment part of the report embraces, in depth CD33 antigen inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CD33 antigen inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CD33 antigen inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve CD33 antigen inhibitors.CD33 antigen inhibitors Emerging Drugs Chapters
This segment of the CD33 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.CD33 antigen inhibitors Emerging Drugs
Hu CD33 BsAb: Y-mAbs Therapeutics HuCD33-BsAb is a product candidate designed for the treatment of hematological cancers expressing CD33, a transmembrane receptor expressed on cells of myeloid lineage. An open label, first in human dose escalation trial in pediatric patients with relapsed or refractory acute myeloid leukemia to assess the safety and tolerability of increasing doses of CD33xCD3 BsAb administered subcutaneously has beeninitiated.CD33 antigen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different CD33 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:Major Players in CD33 antigen inhibitors
There are approx. 4+ key companies which are developing the therapies for CD33 antigen inhibitors. The companies which have their CD33 antigen inhibitors drug candidates in the most advanced stage, i.e. phase I include Y-mAbs Therapeutics.Phases
This report covers around 4+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
CD33 antigen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Peptides
- Polymer
- Small molecule
- Product Type
CD33 antigen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD33 antigen inhibitors therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD33 antigen inhibitors drugs.CD33 antigen inhibitors Report Insights
- CD33 antigen inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
CD33 antigen inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:- How many companies are developing CD33 antigen inhibitors drugs?
- How many CD33 antigen inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD33 antigen inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CD33 antigen inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CD33 antigen inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryDrug profiles in the detailed report…..Drug profiles in the detailed report…..CD33 antigen inhibitors Key CompaniesCD33 antigen inhibitors Key ProductsCD33 antigen inhibitors- Unmet NeedsCD33 antigen inhibitors- Market Drivers and BarriersCD33 antigen inhibitors- Future Perspectives and ConclusionCD33 antigen inhibitors Analyst ViewsCD33 antigen inhibitors Key CompaniesAppendix
CD33 antigen inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Early Stage Products (Phase I)
HuCD33 BsAb: Y-mAbs Therapeutics
Preclinical Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- PersonGen Biomedicine
- Y-mAbs Therapeutics
- Alector
- GT Biopharma
- iCell Gene Therapeutics
